NHS Wales

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

Retrieved on: 
Thursday, February 8, 2024

“This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.

Key Points: 
  • “This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.
  • We look forward to the publication of Final Guidance shortly.”
    NICE is recommending on label access to ILUVIEN as an option for treating visual impairment caused by chronic DME in phakic eyes.
  • NHS England has agreed with the Integrated Care Boards (ICB’s) to provide funding to implement this guidance 30 days after publication.
  • NHS Wales will usually fund within 2 months of the final draft guidance.

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

Retrieved on: 
Monday, December 4, 2023

NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.

Key Points: 
  • NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
  • This published report informs UK doctors, patients, and other interested parties that NICE has started the review of Multikine and is soliciting public comment.
  • The NICE briefing includes the following statements:
    “The current standard of care for locally advanced SCCHN is an aggressive combined modality therapy.
  • According to Cancer Research UK , an average of 12,400 cases of head and neck cancer are diagnosed each year in the UK.

The Lancet Oncology Publishes Results from SYMPLIFY, The First Prospective Study of a Multi-Cancer Early Detection Test in a Symptomatic Patient Population

Retrieved on: 
Tuesday, June 20, 2023

“For the majority of cancers, there are no organized screening programs and most patients diagnosed with cancer first attend primary care with symptoms.

Key Points: 
  • “For the majority of cancers, there are no organized screening programs and most patients diagnosed with cancer first attend primary care with symptoms.
  • “In the SYMPLIFY study, a significant minority of cancers were diagnosed in organs that were different from those originally suspected, given the symptoms experienced.
  • It is also encouraging to see the performance of the test in esophagus, stomach, liver, pancreas and bile duct cancers.
  • We look forward to using these results to further improve test performance in this patient population.”
    The University of Oxford sponsored the SYMPLIFY study and was responsible for data collection, analysis and interpretation.

Wirral University Teaching Hospital Modernizes Training with LMS365 on NHSmail Central Tenant

Retrieved on: 
Monday, June 19, 2023

By automating their training structure and introducing a more efficient method to train healthcare professionals on internal systems and clinical application training, the teaching hospital is set to advance its modernization and adoption goals.

Key Points: 
  • By automating their training structure and introducing a more efficient method to train healthcare professionals on internal systems and clinical application training, the teaching hospital is set to advance its modernization and adoption goals.
  • With LMS365 now available within the central tenant, other NHS organizations can effortlessly activate the comprehensive course catalog upon purchasing an LMS365 license.
  • - Paul Jones, Head of Clinical Applications
    Previously, clinical systems training at Wirral University Teaching Hospital relied solely on face-to-face classroom sessions.
  • - Chris Mason, CIO, Wirral University Teaching Hospital

GRAIL and University of Oxford to Present Results From First Prospective Study of Multi-Cancer Early Detection in a Symptomatic Patient Population at 2023 ASCO Annual Meeting

Retrieved on: 
Friday, June 2, 2023

SYMPLIFY is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented to primary care and were referred for diagnostic follow-up for suspicion of cancer.

Key Points: 
  • SYMPLIFY is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented to primary care and were referred for diagnostic follow-up for suspicion of cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230601006068/en/
    “Earlier cancer detection and subsequent intervention has the potential to greatly improve patient outcomes.
  • Within the study, 368 (6.7%) of the 5,461 evaluable patients were diagnosed with cancer through standard of care.
  • “We are committed to diagnosing cancers earlier, when they can be cured, and this study is an important step on that journey.

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

Retrieved on: 
Wednesday, April 5, 2023

ILAP was established in 2021 to reduce the time to market for innovative medicines in the United Kingdom.

Key Points: 
  • ILAP was established in 2021 to reduce the time to market for innovative medicines in the United Kingdom.
  • In addition, patients are also considered key partners and the patient voice is integrated at every development stage.
  • “We are delighted that MHRA has recognized the potential of AD04™ at same time we are launching our confirmatory trial,” said Jeffrey Madden, chief executive officer of ADvantage.
  • We hope this AD04 trial with ILAP designation will bring us one step closer,” he concluded.

Ibex Secures PathLAKE Contracts to Roll Out AI-based Cancer Diagnostics to UK Hospitals

Retrieved on: 
Tuesday, March 7, 2023

TEL AVIV, Israel , March 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the receipt of multiple contract awards from the PathLAKE consortium  to provide Artificial Intelligence (AI) solutions to support cancer diagnosis at 25 NHS Trusts.

Key Points: 
  • TEL AVIV, Israel , March 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the receipt of multiple contract awards from the PathLAKE consortium  to provide Artificial Intelligence (AI) solutions to support cancer diagnosis at 25 NHS Trusts.
  • PathLAKE is a UK center of excellence consortium, founded by Innovate UK, that is delivering AI innovation in pathology across leading NHS Trusts and UK universities including Nottingham University Hospitals, University Hospitals Coventry & Warwickshire, and Oxford University Hospitals.
  • Cambridge University Hospitals is one of the Trusts to subsequently select Ibex to support its pathologists by augmenting diagnostic workflows with enhanced quality, accuracy and efficiency.
  • "We are extremely honored to be recognized by PathLAKE as the leading provider of AI solutions in pathology," said Richard Nicholson, Director of Sales, UK at Ibex.

TOMI Expands Globally with Purchase from National Health Services (NHS) Wales

Retrieved on: 
Tuesday, January 17, 2023

FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain.

Key Points: 
  • FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain.
  • NHS Wales is a publicly funded healthcare system in Wales that provides emergency services as well as primary, secondary, specialist services, and funding for other healthcare service initiatives.
  • NHS Wales is currently constructing facilities mainly for the expansion of their aseptic pharmaceutical manufacturing.
  • TOMI continues to increase its presence and maintain strong partnerships and distributors of SteraMist disinfection throughout the world.

CMR Surgical announces more than 100 Versius systems installed globally

Retrieved on: 
Thursday, November 17, 2022

CMR Surgical (CMR) the global surgical robotics business today provides an update on progress, as the Company announces it has now installed more than 100 Versius Surgical Robotic Systems commercially.

Key Points: 
  • CMR Surgical (CMR) the global surgical robotics business today provides an update on progress, as the Company announces it has now installed more than 100 Versius Surgical Robotic Systems commercially.
  • CMR has continued to scale-up rapidly and has now installed the next-generation robotic system across Europe, Asia, Australia, Latin America, and the Middle East.
  • Per Vegard Nerseth, Chief Executive Officer of CMR Surgical, comments: This is a significant milestone for CMR as we continue to deliver on our ambitious commercial plans.
  • If you wish to see more, please contact CMR Surgical at:

CMR Surgical announces more than 100 Versius systems installed globally

Retrieved on: 
Thursday, November 17, 2022

CMR Surgical (CMR) the global surgical robotics business today provides an update on progress, as the Company announces it has now installed more than 100 Versius Surgical Robotic Systems commercially.

Key Points: 
  • CMR Surgical (CMR) the global surgical robotics business today provides an update on progress, as the Company announces it has now installed more than 100 Versius Surgical Robotic Systems commercially.
  • CMR has continued to scale-up rapidly and has now installed the next-generation robotic system across Europe, Asia, Australia, Latin America, and the Middle East.
  • Per Vegard Nerseth, Chief Executive Officer of CMR Surgical, comments: This is a significant milestone for CMR as we continue to deliver on our ambitious commercial plans.
  • If you wish to see more, please contact CMR Surgical at: